Published by Josh White on 11th March 2021
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.